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Abstract
Background: Reproductive function following chemotherapy is of increasing importance given that survival rates are 
improving. We assessed whether a gonadotropin-releasing hormone antagonist (GnRHant; cetrorelix) could promote 
ovarian protection against damage due to chemotherapy.
Methods: Forty-two female Wistar rats were used in this study. Animals were divided into four groups: group I (n = 9) 
received placebo twice; group II (n = 12) received placebo + cyclophosphamide (CPA); group III (n = 12) received 
GnRHant + CPA; and group IV (n = 9) received GnRHant + placebo. After medication, the estrous cycle was studied 
through vaginal smears. Rats were mated, pregnancy was documented and the number of live pups evaluated. 
Afterwards, rat ovaries were removed and prepared for histological studies. The ovarian cross-sectional area was 
measured and follicles were counted.
Results: Cyclic changes in vaginal smears were observed in all but one animal after treatment, but group II had a 
significantly lower rate of animals with proestrus or estrus (p < 0.01). The offspring was markedly reduced by CPA 
treatment (group II, 3.00 +/- 1.33 pups vs. group I, 11.44 +/- 0.78 pups, p < 0.01) and this effect was partly reversed by 
pre-treatment with GnRHant (group III, 7.00 +/- 1.31 pups). The ovarian cross-sectional area was not significantly 
different between groups, neither was the number of individual follicle types. However, rats in Group IV had a higher 
total number of ovarian follicles than those in the control group (17.1 +/- 1.22 vs. 10.9 +/- 0.70, p < 0.05).
Conclusion: The use of a GnRHant before CPA chemotherapy provided protection of fertility.
Background
Current advances in cancer treatment have substantially
increased the survival of reproductive age women with
cancer [1-4] and, as survival rates improve, the quality of
life of these patients deserves more attention. The loss of
r e p r o d u c t i v e  f u n c t i o n  i s  o n e  o f  t h e  m o s t  i m p o r t a n t
adverse effects of chemotherapy. Cancer treatment with
DNA alkylating agents, such as cyclophosphamide (CPA),
can lead to impaired fertility or ovarian failure, resulting
in premature menopause [5]. CPA is widely used in the
treatment of malignant neoplasms and some auto-
immune diseases, including rheumatoid arthritis and sys-
temic lupus erythematosus.
New strategies have been developed to prevent the
adverse effects of chemotherapy on ovarian function.
Dividing cells are known to be more sensitive to the cyto-
toxic effects of the alkylating agents than are cells at rest.
I t  h a s  b e e n  s u g g e s t e d  t h a t  i n h i b i t i o n  o f  t h e  p i t u i t a r y -
gonadal axis would reduce the rate of oogenesis and
thereby render the germinal epithelium less susceptible
to the effects of chemotherapy [1]. For this purpose, the
use of gonadotropin-releasing hormone (GnRH) agonists
prior to chemotherapy is currently under investigation.
Ozcelik et al. [6] and Tan et al. [7] showed a protective
effect of a GnRH agonist on chemotherapy induced ovar-
ian gonadoxicity in mice and rats, respectively. The same
protective effect was found in a randomized clinical trial
[8] and a meta-analysis [9]. At least four ongoing ran-
domized clinical trials are addressing the issue of ovarian
preservation with GnRH agonists [10-13].
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GnRH agonists have an initial stimulatory effect on the
gonads, thus delaying ovarian suppression, which is
expected to occur after a 14-day period. This waiting time
is crucial when the treatment of cancer is proposed [14].
In contrast, GnRH antagonists cause immediate ovarian
suppression by competitively blocking GnRH receptors
in the pituitary. With their immediate onset of action,
GnRH antagonists may be suitable for use immediately
before initiation of chemotherapy. However, there are no
animal studies to date that have assessed the role of a
GnRH antagonist on fertility protection during chemo-
therapy. We also have not found any published clinical
trial using GnRH antagonist with this objective.
Thus, the aim of the present study was to investigate
whether the administration of a GnRH antagonist prior
to the administration of CPA in female rats would pre-
vent ovarian damage and promote fertility preservation.
Methods
This controlled experimental study was carried out at the
animal research unit of the Faculdade de Medicina, Uni-
versidade Federal Minas Gerais (UFMG), at Belo Hori-
zonte, Brazil. The study followed the international ethical
guidelines and was approved by UFMG Ethics Commit-
tee on Animal Experimentation.
Animals
A total of 42 female Wistar rats 60 days old with a mean
weight of 350 g were used. Animals were obtained from
the animal research facility at the Instituto de Ciências
Biológicas of UFMG. Prior to the study, the estrous cycle
was confirmed by vaginal cytology, and only those rats
with an estrous cycle of 4-7 days were included [15].
Rats were kept in Alesco plastic cages, model ALE.MIL.
01. 05, measuring 70 × 40 × 20 cm. No more than five ani-
mals were kept together in each cage. Room temperature
was maintained at 24 ± 2°C, with a 12-hour light cycle
and adequate air supply. Water and rat food pellets were
available ad libitum.
Medication
GnRH antagonist (cetrorelix)
A diluted solution of 0.1 mg/kg of cetrorelix acetate in
distilled water and 5% mannitol was administered intrap-
eritoneally 1 hour before the CPA injection [16,17]. Previ-
ous studies had shown that the maximum serum
concentration of cetrorelix is reached after 2 hours. This
dose is known to inhibit the luteinizing hormone surge in
about 1 hour.
Cyclophosphamide
A diluted solution of 6 mg/kg of CPA in 0.9% sodium
chloride (saline), resulting in a 1 mg/mL dose, was
administered intraperitoneally. This dose is reported to
have a mortality rate of 24% and to induce a decrease in
fertility in about 70% of the animals [18,19].
Placebo
Saline solution was used as placebo.
Drug administration schedule
Drugs were injected aseptically via the peritoneum, on
the inferior abdominal area next to the right hind leg, in
three cycles of five consecutive days followed by a 2-day
drug-free interval. Drugs were administered in the morn-
ings and the treatment course took 3 weeks to complete,
according to the following schedule:
• Group I (control; n = 9). Initial treatment: placebo
injection. After 1 hour, another placebo injection was
given.
• Group II (n = 12). Initial treatment: placebo injec-
tion. After 1 hour, a CPA injection was given.
• Group III (n = 12). Initial treatment: GnRH antago-
nist (cetrorelix) injection. After 1 hour, a CPA injec-
tion was given.
• Group IV (n = 9). Initial treatment: GnRH antago-
nist (cetrorelix) injection. After 1 hour, a placebo
injection was given.
Doses were adjusted weekly based on the weight of the
animal.
Evaluation of fertility
The day after the final treatment, the rats were submitted
to a new 8-day estrous cycle study in order to confirm
and document fertility status. They were then allowed to
mate with adult male Wistar rats. Mating was confirmed
by the presence of spermatozoa on microscopic analysis
of vaginal wash. Confirmation was considered as the first
day of pregnancy. After 21 days, the offspring were
counted.
After delivery, the rats were killed with a peritoneal
injection of 35 mg sodium thiopental and underwent
bilateral oophorectomy. Each ovary was entirely cut into
serial longitudinal sections and follicle count was per-
f o r m e d  a t  f o u r  s e c t i o n s  d i s t a n t  f r o m  e a c h  o t h e r  b y
approximately 200 μm. This method was chosen consid-
ering (i) that other published studies with similar design
evaluated a few random ovarian sections [6,20]; (ii) there
is a strong correlation between serial and random section
counting for the number of small follicles [20]; and (iii)
keeping a regular distance between counted sections
would avoid duplicate counting of large follicles. The sec-
tions were stained with hematoxylin and eosin and the
total number of each type of follicle (primordial, primary,
preantral and antral) and corpora lutea was computed for
every section, then used to calculate the average number
of follicles per section for every animal. The largest ovar-
ian section from each rat was selected and its area wasLemos et al. Reproductive Biology and Endocrinology 2010, 8:51
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calculated using Image Pro-plus version 6.0 software
(Media Cybernetics, Bethesda, MD, USA).
Statistical analysis
Results were analyzed with Prism version 4.0 software
(GraphPad, La Jolla, CA, USA). Data were normally dis-
tributed and therefore expressed as mean ± standard
error (SE). Differences between groups were tested by
one-way analysis of variance (ANOVA). If a significant
overall difference was found, the post hoc Newman-Keuls
test was computed for multiple comparisons. Qualitative
data were evaluated by likelihood ratio chi-square test. A
value of p < 0.05 was considered statistically significant.
Results
Following treatment, two rats died in Group II and none
in the remaining groups, leaving for analysis n = 9, n = 10,
n = 12 and n = 9 animals in groups I, II, III and IV, respec-
tively.
Eight-day samples of estrous cycles following treat-
ments are shown in Figure 1. Cyclic changes in vaginal
cytology were observed after treatment in all but two ani-
mals (rat 2 from Group II and rat 12 from group III),
which entered permanent diestrus. However, CPA
induced a significantly lower rate of cycles containing at
least one proestrus and/or estrus, and this effect of CPA
was reversed by pre-treatment with GnRHant (chi-square
= 12.42, p < 0.01). Those cycles were detected in 9/9 rats
from Group I, 5/10 rats from group II, 10/12 rats from
group III and 9/9 rats from group IV (Table 1).
Twenty-one days after mating, the offspring from each
animal was counted. Figure 2 shows a comparison of the
mean number of live pups per litter in each group. The
offspring was markedly reduced by CPA treatment
(Group II, 3.00 ± 1.33 pups vs. Group I, 11.44 ± 0.78 pups,
p < 0.01) and this effect was partly reversed by pre-treat-
ment with GnRHant (Group III, 7.00 ± 1.31 pups). The
group that received only GnRHant (Group IV, 10.11 ±
0.61 pups) did not differ from the placebo-treated con-
trols. There was no case of perinatal death and the pups
were apparently of normal size and morphology.
The mean ovarian cross-sectional area ranged from
4.30 to 5.45 mm2  and was not significantly different
between groups (Table 2). The average numbers of pri-
mordial and primary follicles, preantral follicles, antral
follicles and corpora lutea were not altered by treatment
with CPA or CPA + GnRHant (Table 2). However, the
animals treated only with GnRHant (Group IV) had a
mild increase in the counting of preantral and antral folli-
cles, resulting in a significant increase of the sum of folli-
cles (17.1 ± 1.22) compared to the control group (10.9 ±
0.70 follicles, p < 0.05, Table 2).
Discussion
Protection against the adverse effects of CPA on ovarian
function is highly desirable given the number of women
of reproductive age with disorders that are treated with
CPA, and the improvement of survival rates in patients
undergoing chemotherapy [21]. Evidence suggests that
prepubertal patients are less sensitive to the adverse
effects of chemotherapy [22]. Thus, drugs that are able to
make the gonads quiescent and less sensitive to chemo-
therapy-induced cytotoxicity could protect fertility.
Delaying cancer treatment can pose serious risks to the
patient. Therefore, a drug that promotes immediate ovar-
ian suppression is preferable. Given the immediate mech-
anism of action of GnRH antagonists, their use would
eliminate the 14-day waiting period required to suppress
ovarian activity using GnRH agonists.
In this study, the mean litter size of rats treated with a
GnRH antagonist plus CPA was greater than that in the
group that received only CPA without GnRH antagonist
co-treatment, suggesting that antagonists may protect
r e p r o d u c t i v e  f u n c t i o n .  T h i s  r e s u l t  m a y  b e  d u e  t o  t h e
immediate interruption of gonadotropic stimulus on the
ovaries, causing a reduction in mitosis within the gonad
and a transient follicle growth arrest, which renders the
follicles less susceptible to the aggression of chemother-
Table 1: Summary of estrous cycles recorded during 8 days, shortly after the conclusion of chemotherapy course.
Group I
(placebo)
Group II
(CPA)
Group III
(GnRHant + CPA)
Group IV
(GnRHant)
Chi-Square
(p value)
Number of 
surviving rats per 
group
91 0 1 29 -
Number of rats 
with a cyclic 
pattern (%)
9
(100)
9
(90)
11
(92)
9
(100)
2.50
(p = 0.48)
Number of rats 
with estrus/
proestrus (%)
9
(100)
5
(50)
10
(83)
9
(100)
12.42
(p < 0.01)
CPA, cyclophosphamide; GnRHant, gonadotropin-releasing hormone antagonist (cetrorelix).Lemos et al. Reproductive Biology and Endocrinology 2010, 8:51
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Figure 1 Individual plots showing the estrous cycles recorded during 8 days, shortly after the conclusion of chemotherapy course with pla-
cebo, cyclophosphamide (CPA), cetrorelix (GnRHant) plus CPA, and GnRHant. The vertical axes represent the phases of estrous cycle (D = di-
estrus; M = metaestrus; P = proestrus; E = estrus) and the horizontal axes represent the time (days).
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apy [22,23]. However, these mechanisms deserver further
investigation in order to demonstrate their precise role in
ovarian chemoprotection, and also to test whether
GnRHant has any direct effect on the ovaries.
Estrous cycles were not permanently suppressed by
CPA, at least in the short term following the chemother-
apy course. This result is similar to that reported by
Ghosh et al. [24], who noted, nevertheless, an increase in
the metaestrus and diestrus and a decrease in the
proestrus and estrus. This was confirmed here by the
lower number of rats showing estrus or proestrus after
CPA treatment, compared to placebo. Moreover, the
reversion of this abnormality by pre-treatment with
GnRH antagonist is suggestive of a protective effect on
ovarian endocrine function.
In the present study we have not observed substantial
changes in ovarian morphology in any treatment groups,
while previous studies have shown a decrease in the num-
ber of primordial follicles following chemotherapy
[6,7,25]. A possible explanation for this difference could
be because we evaluated ovarian morphology after a full
term gestation, while others have extracted the ovaries
soon after chemotherapy, without the interference of
pregnancy. However, this study was designed to evaluate
not only potential fertility, through ovarian morphology
and estrous cycle, but actual fertility by assessing preg-
nancy and live births, which only allowed oophorectomy
to be performed after gestation and delivery.
A significant decrease in ovarian cross-sectional area
following CPA administration was not seen in our study.
The most likely explanation for this is that the rats were
submitted to a single course (three cycles) of chemother-
apy, which is enough to cause fertility impairment, but
may have been insufficient to change ovarian size. It is
not clear whether several courses of CPA would decrease
the ovarian cross-sectional area, or whether the follicles
that were found in the specimens were viable; that is,
whether they would be able to produce mature follicles
and a subsequent pregnancy. Moreover, although the
number of follicles and ovarian cross-sectional area were
not altered by CPA treatment, the number of pups in the
offspring was lower, indicating a deleterious effect on fer-
tility. It is important to note that ovarian morphology
does not necessarily reflect its endocrine or reproductive
function. Therefore, the residual follicles that we
observed after chemotherapy and pregnancy may not be
all normally functional, as suggested by the fertility
impairment of rats receiving only CPA.
The results of this study support the hypothesis about
fertility protection by GnRH analogs in female rats
undergoing chemotherapy with CPA. Several studies
Figure 2 Number of live pups per litter in rats treated with place-
bo (Group I), cyclophosphamide (Group II), cetrorelix plus cyclo-
phosphamide (Group III), and cetrorelix (Group IV). Data are 
expressed as means ± SE and the group means were compared by the 
Newman-Keuls test.
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Table 2: Ovarian morphological parameters in rats following chemotherapy and pregnancy.
Group I
(placebo)
Group II
(CPA)
Group III
(GnRHant + CPA)
Group IV
(GnRHant)
Primordial and primary 
follicles
3.4 ± 0.53 2.9 ± 0.38 3.8 ± 0.46 3.8 ± 0.52
Preantral follicles 3.0 ± 0.24 3.4 ± 0.54 3.9 ± 0.48 4.1 ± 0.39
Antral follicles 4.4 ± 0.34 5.0 ± 0.60 6.6 ± 0.53 6.4 ± 0.50
Corpora lutea 4.2 ± 0.40 3.3 ± 0.50 3.4 ± 0.40 4.1 ± 0.30
Total number of 
follicles
10.9 ± 0.70 11.6 ± 1.14 14.3 ± 1.26 17.1 ± 1.22*
Ovarian cross-
sectional area (mm2)
5.45 ± 0.50 4.30 ± 0.56 4.56 ± 0.89 4.62 ± 0.66
Data are expressed as mean ± standard error. *p < 0.05 vs. Group I.
CPA, cyclophosphamide; GnRHant, gonadotropin-releasing hormone antagonist (cetrorelix).Lemos et al. Reproductive Biology and Endocrinology 2010, 8:51
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have highlighted this protection with the use of GnRH
agonists. Most of the work are still experimental, but
some clinical studies are now being conducted in this
field. Although some cancer centers are already offering
this option to protect ovarian function, both the Ameri-
can Society for Reproductive Medicine (ASRM) and the
American Society of Clinical Oncology (ASCO) discour-
age this practice due to insufficient scientific evidence
[26,27]. However, these same entities, based on the
results found by animal studies, encourage the develop-
ment of research in this area and recommend this as a
promising possibility. The advantage of the use of GnRH
antagonists instead of agonists would be their ability to
promote a prompt gonadal suppression, allowing the
immediate start of chemotherapy, which could be crucial
in the treatment of cancer.
To the best of our knowledge, only two published stud-
ies have evaluated the use of cetrorelix for ovarian protec-
tion in animals subjected to chemotherapy with CPA.
Both studies investigated only the number of primordial
follicles in female mice treated with CPA, and none of
them directly assess fertility. Meirow et al. [25] concluded
that the use of cetrorelix attenuates the reduction in the
number of primordial follicles caused by CPA, suggest-
ing, therefore, ovarian protection with the use of cetrore-
lix. This protection was not found by Danforth et al.
evaluating the primordial follicles in female mice sub-
jected to a single dose of CPA and GnRH antagonist [28].
However, in the latter study the results should be inter-
preted more cautiously because the number of animals
was small, the regimen of chemotherapy was a single dose
and the only variable considered was the number of pri-
mordial follicles.
The safety of the use of cetrorelix in humans is already
consolidated and this drug is widely used for ovarian
blockade in patients submitted to assisted reproduction
techniques. This proven safety can facilitate the develop-
ment of clinical studies with the goal proposed here.
Conclusion
The administration of GnRH antagonist cetrorelix had a
protective effect on the fertility of rats undergoing che-
motherapy with CPA.
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